Hydroxocobalamin - EMD Pharmaceuticals

Drug Profile

Hydroxocobalamin - EMD Pharmaceuticals

Alternative Names: Cyanokit; Hydroxocobemine

Latest Information Update: 25 May 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator EMD Pharmaceuticals
  • Class Corrinoids; Vitamin B12 analogues; Vitamins
  • Mechanism of Action Chelating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Marketed Poisoning

Most Recent Events

  • 24 May 2011 Launched for Poisoning in Canada (IV)
  • 01 Mar 2011 King Pharmaceuticals has been acquired and merged into Pfizer
  • 06 Apr 2010 Hydroxocobalamin licensed to Swedish Orphan Biovitrum in Ireland, the UK and the Netherlands
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top